Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.72 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22867035 | 0.91 | CD274 (0.62) | CD274 | |
| SCHEMBL22820882 | 0.89 | CD274 (0.60) | CD274 | |
| SCHEMBL29964955 | 0.89 | CD274 (0.60) | CD274 | |
| SCHEMBL22866949 | 0.88 | CD274 (0.59) | CD274PDCD1 | |
| SCHEMBL22762970 | 0.85 | CD274 (1.00) | CD274 | |
| SCHEMBL22821166 | 0.84 | CD274 (0.75) | CD274PDCD1 | |
| SCHEMBL29965736 | 0.84 | CD274 (0.75) | CD274PDCD1 | |
| SCHEMBL29455513 | 0.84 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL29455401 | 0.82 | CD274 (0.75) | CD274 | |
| SCHEMBL22866954 | 0.82 | CD274 (0.67) | CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002229-A1 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002229-A1 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.